Lioresal (Baclofen)

Baclofen in Lioresal binds to GABA_B receptors in the spinal cord, which reduces the release of excitatory neurotransmitters. This inhibition dampens the activity of motor neurons, leading to a decrease in muscle tone and the relief of spastic muscle contractions.

The dose of Lioresal is individualized. A qualified prescriber determines the appropriate concentration and infusion rate based on the patient’s clinical condition, response to therapy and safety considerations. Dosing is adjusted during titration and maintenance phases under medical supervision.

Safety data for intrathecal baclofen in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Physicians should discuss the uncertainties with the patient before initiating therapy.

To request Lioresal, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Intrathecal baclofen (Lioresal) delivers the drug directly to the spinal fluid, achieving higher local concentrations with lower systemic exposure compared with oral baclofen. This often results in greater spasticity control and fewer systemic side effects, especially in patients who do not respond adequately to oral therapy.

Lioresal should be stored at ambient temperature, preferably below 25 °C, protected from light and moisture. Keep the solution in its original sealed container until use, and avoid freezing or shaking the vial to maintain product integrity.

Lioresal is administered via an implanted intrathecal pump that delivers a continuous infusion of baclofen into the cerebrospinal fluid. The pump is surgically placed under the skin, and dosing is programmed by a healthcare professional based on the patient’s therapeutic response.

The most serious risks include respiratory depression, severe hypotension and the possibility of seizures, especially if the infusion is abruptly stopped. Patients should be monitored closely for signs of respiratory compromise, sudden loss of muscle tone or any neurologic changes.

Lioresal is contraindicated in patients with known hypersensitivity to baclofen or any component of the formulation. It should also be avoided in individuals with uncontrolled severe respiratory disorders, acute urinary retention, or those who cannot be monitored for potential withdrawal if the pump fails.